The actual benefit of intraoperative radiation therapy using 50 kV x‐rays in early breast cancer: A retrospective study of 676 patients

Abstract

This French study reports the 5-year results of partial-breast irradiation using intraoperative radiation therapy (IORT) with 50 kV x-rays, in select early breast cancer patients. We report a retrospective analysis of 676 consecutive early breast cancer patients treated between November 2011 and December 2015 by partial-breast irradiation using the INTRABEAM ® system. Patients were highly selected based on the ASTRO and GEC-ESTRO criteria and underwent breast-conservative surgery and IORT, completed with additional whole-breast irradiation (WBI) when unexpected unfavorable prognostic factors were found at the final pathology report. Patients' outcomes relative to local and distant control, overall and breast cancer-specific survival, and toxicity are presented, as well as rates of additional WBI. Additional WBI was mandatory in one third of patients (31%), mainly due to lymph node involvement and extensive intraductal component. With a median follow-up time of 54 months,

Intraoperative radiation therapy for early-stage breast cancer: a single-institution experience

“…However, with longer follow-up, a recent 2021 update of TARGIT-R reported a 5-year IBTR rate of 6.6% [ 20 ]. A summary of photon IORT trials is shown in Supplementary File — Table S2 [ 18 , 20 – 25 ].…”

Calculated and measured radiation dose in water for the low energy Xoft Axxent eBT X-ray source

“…In this approach, the rate of tumor proliferation is reduced and local tumor control is achieved (28). Even though IORT has always been taken advantage of in the treatment of early-stage breast cancer, it is recently used in boost therapy for whole breast irradiation in high risk breast cancer patients with a favorable breast cancer prognosis (29).…”

The TARGIT-A Randomized Trial: TARGIT-IORT Versus Whole Breast Radiation Therapy: Long-Term Local Control and Survival

“…Multiple prospective non-randomised studies have published their results of using TARGIT-IORT, with similar outcomes in over 3000 patients treated with TARGIT-IORT from France, Germany, Denmark, Switzerland, and others [16][17][18][19][20][21] . By 2019, over 260 centres in 38 countries worldwide had treated over 45,000 breast cancer patients with TARGIT-IORT (https://targit.org.uk) 22 .…”